title: Managing migraine: strategies for successful patient outcomes.
abstract: This article highlights information from the 2000 National Conference for Nurse Practitioners symposium held in Washington, D.C., on November 9, 2000. It was sponsored by The Nursing Institute of Springhouse Corporation and funded by an unrestricted educational grant from Merck & Co., Inc. The firsttopic, "Overview of Migraine: Compelling Effects on Patients and Society," was presented for Dedie Downey Russell, CNP, ANP/GNP, MS. The second topic, "Understanding Pathophysiology: Evolving from Traditional to Current Therapeutic Options," was presented by Dara G. Jamieson, MD. Maureen Moriarty-Sheehan, MS, CRNP, who also served as chairperson, presented the third topic, "Developing a Management Plan for Optimal Patient Benefit."
authors.affiliation: Speed Headache Associates, PA, Baltimore, Maryland, USA.
authors.forename: M
authors.initials: M
authors.lastname: Moriarty-Sheehan
authors.forename: D G
authors.initials: DG
authors.lastname: Jamieson
authors.forename: D D
authors.initials: DD
authors.lastname: Russell
mesh_terms: D000208:Acute Disease; D001294:Attitude to Health; D003937:Diagnosis, Differential; D007255:Information Services; D020407:Internet; D008881:Migraine Disorders / Q000175:diagnosis* / Q000209:etiology / Q000503:physiopathology / Q000523:psychology / Q000628:therapy*; D009722:Nurse Practitioners; D011320:Primary Health Care / Q000379:methods*; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use; D018170:Sumatriptan / Q000627:therapeutic use; D017749:Total Quality Management / Q000458:organization & administration; D016896:Treatment Outcome; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
chemical_list: D017366:Serotonin Receptor Agonists; D014662:Vasoconstrictor Agents; D018170:Sumatriptan